Alzahrani Ali S, Moria Yosra, Mukhtar Noha, Aljamei Hadeel, Mazi Sedra, Albalawi Lina, Aljomaiah Abeer
Department of Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
J Endocr Soc. 2020 Nov 11;5(1):bvaa178. doi: 10.1210/jendso/bvaa178. eCollection 2021 Jan 1.
Controversy surrounds the extent and intensity of the management of American Thyroid Association (ATA) intermediate- and low-risk patients with differentiated thyroid cancer (DTC). Understanding the natural history and factors that predict outcome is important for properly tailoring the management of these patients.
This work aims to study the natural course and predictive factors of incomplete response to therapy in low- and intermediate-risk DTC.
We studied a cohort of 506 consecutive patients [418 women (82.6%) and 88 men (17.4%)] with low and intermediate risk with a median age of 35 years (interquartile range [IQR], 27-46 years). We analyzed the natural course and the predictive factors of biochemically or structurally incomplete response.
Of 506 patients studied, 297 (58.7%) patients were in the low-risk group and 209 (41.3%) were in the intermediate-risk group. Over a median follow-up of 102 months (IQR, 66-130 months), 458 (90.5%) patients achieved an excellent response, 17 (3.4%) had a biochemically incomplete status, and 31 (6.1%) had a structurally incomplete status. In univariable and multivariable analyses, age (≥ 33 years) ( < .0001, odds ratio 1.06 [1.04-1.08]) and lateral lymph node metastasis (LNM; < .0001, odds ratio 3.2 [1.7-5.9]) were strong predictive factors for biochemically and structurally incomplete response to therapy. Sex, tumor size, multifocality, extrathyroidal extension, and lymphovascular invasion did not predict incomplete response to therapy.
Patients with low- and intermediate-risk DTC have favorable outcomes. Age and lateral LNM are strong predictors of an incomplete response to therapy. This suggests that older patients and those with LNM should be managed and followed up more actively than younger patients and those without LNM.
美国甲状腺协会(ATA)对分化型甲状腺癌(DTC)中低风险患者的管理程度和强度存在争议。了解其自然病程和预测预后的因素对于合理调整这些患者的管理至关重要。
本研究旨在探讨低风险和中风险DTC治疗反应不完全的自然病程及预测因素。
我们研究了一组连续的506例患者[418名女性(82.6%)和88名男性(17.4%)],他们为低风险和中风险患者,中位年龄为35岁(四分位间距[IQR],27 - 46岁)。我们分析了生化或结构反应不完全的自然病程及预测因素。
在研究的506例患者中,297例(58.7%)患者属于低风险组,209例(41.3%)属于中风险组。中位随访102个月(IQR,66 - 130个月),458例(90.5%)患者获得了良好反应,17例(3.4%)生化状态不完全,31例(6.1%)结构状态不完全。在单变量和多变量分析中,年龄(≥33岁)(P <.0001,比值比1.06[1.04 - 1.08])和侧方淋巴结转移(LNM;P <.0001,比值比3.2[1.7 - 5.9])是生化和结构治疗反应不完全的强预测因素。性别、肿瘤大小、多灶性、甲状腺外侵犯和淋巴管侵犯不能预测治疗反应不完全。
低风险和中风险DTC患者预后良好。年龄和侧方LNM是治疗反应不完全的强预测因素。这表明老年患者和有LNM的患者应比年轻患者和无LNM的患者接受更积极的管理和随访。